Meningococcal vaccine group B - GlaxoSmithKline

Drug Profile

Meningococcal vaccine group B - GlaxoSmithKline

Alternative Names: 4CMenB; Bexsero; Four component, meningococcal serogroup B vaccine (4CMenB) - GlaxoSmithKline; MenB; MenB+OMV NZ - GlaxoSmithKline; Meningococcal B recombinant vaccine - GlaxoSmithKline; Multi-component meningococcal B vaccine (Bexsero) - GlaxoSmithKline; rMenB+OMV NZ

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Norwegian Institute of Public Health; Novartis
  • Developer GlaxoSmithKline; Novartis
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 26 Oct 2016 Safety data from a phase I trial in Meningococcal group B infections presented at the IDWeek-2016
  • 01 Sep 2016 Novartis completes a phase IIIb trial in Meningococcal group B infections (Prevention; In adolescents) in Australia, Canada and Chile (NCT02446743)
  • 13 May 2016 Registered for Meningococcal group B infections (Prevention) in Argentina, Brazil, Uruguay (IM) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top